Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWWY | ISIN: US92859E2072 | Ticker-Symbol:
NASDAQ
31.03.25
19:25 Uhr
2,900 US-Dollar
-0,080
-2,68 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIVOS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VIVOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEarnings Outlook For Vivos Therapeutics2
18.02.Vivos Therapeutics, Inc: Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm ET.1
VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln
14.02.Vivos Therapeutics, Inc. - 8-K, Current Report-
11.02.Vivos Therapeutics announces up to $50M mixed shelf offering1
29.01.Vivos Therapeutics, Inc. - S-1/A, General form for registration of securities-
22.01.Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders1
22.01.Vivos Therapeutics, Inc. - S-1, General form for registration of securities-
23.12.24Vivos Therapeutics, Inc. - 8-K, Current Report-
23.12.24Vivos Therapeutics announces $3.5 million stock offering2
23.12.24Vivos Therapeutics kündigt Aktienemission im Wert von 3,5 Millionen US-Dollar an3
23.12.24Vivos Therapeutics, Inc: Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules1
10.12.24Cellev8 Nutrition Inc: Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress410WELLINGTON, FL and HIGHLANDS RANCH, CO / ACCESSWIRE / December 10, 2024 / Cellev8 Nutrition Inc. (OTC Pink:CELV) and Vivos Therapeutics, Inc. today announced a strategic joint marketing venture aimed...
► Artikel lesen
27.11.24Vivos Therapeutics, Inc. - 8-K, Current Report1
14.11.24Vivos Therapeutics, Inc. - 8-K, Current Report-
08.10.24InvestorNewsBreaks - Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices2
08.10.24Vivos Therapeutics, Inc: Vivos Therapeutics Granted CPT Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association141LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization...
► Artikel lesen
18.09.24Vivos Therapeutics, Inc: Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring367Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos' DNA appliance now approved...
► Artikel lesen
14.08.24Vivos Therapeutics, Inc: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update324Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives...
► Artikel lesen
27.06.24Vivos Therapeutics, Inc: Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model144LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company" (NASDAQ:VVOS), a leading medical device and technology company specializing in the development...
► Artikel lesen
09.04.24Vivos Therapeutics, Inc: Vivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement755LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and technology company specializing in the development...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1